“…There have been limited studies on T2DM among the global population that has been associated with lower and higher risk ( Böger et al, 2005 , Herder et al, 2008 , Kochetova et al, 2019 , Lee et al, 2021 , Prasad et al, 2007 ) and our study was highly associated with an average risk × 4.3. Consequently, the variant rs2107538 has been studied in various human diseases such as GDM ( Teler et al, 2017 ), PTDM ( Joo et al, 2007 , Jeong et al, 2010 ), cardiovascular ( Mohtavinejad et al, 2021 ) and coronary artery diseases ( Lee et al, 2021 , Ting et al, 2015 , Liu et al, 2012 , Duell et al, 2006 ), myocardial infarction ( Tereshchenko et al, 2011 ), asthma ( Nahas et al, 2012 , Lu et al, 2012 ), prostatic hyperplasia ( Pang et al, 2019 ), and cancers such as prostate cancer ( Kidd et al, 2012 ), oral and pancreatic cancers ( Weng et al, 2010 , Duell et al, 2006 ). Furthermore, these variants were studied in meta -analyses alongside tuberculosis ( Sheng and Qi, 2020b ) and cancer ( Ying et al, 2014 ).…”